Lung Cancer: Diagnosis and Management

Am Fam Physician. 2007 Jan 1;75(1):56-63.

  Patient information: See related handout on smoking cessation.

Lung cancer is the leading cause of cancer-related death in the United States, with an average five-year survival rate of 15 percent. Smoking remains the predominant risk factor for lung cancer. Lung cancers are categorized as small cell carcinoma or non–small cell carcinoma (e.g., adenocarcinoma, squamous cell carcinoma, large cell carcinoma). These categories are used for treatment decisions and determining prognosis. Signs and symptoms may vary depending on tumor type and extent of metastases. The diagnostic evaluation of patients with suspected lung cancer includes tissue diagnosis; a complete staging work-up, including evaluation of metastases; and a functional patient evaluation. Histologic diagnosis may be obtained with sputum cytology, thoracentesis, accessible lymph node biopsy, bronchoscopy, transthoracic needle aspiration, video-assisted thoracoscopy, or thoracotomy. Initial evaluation for metastatic disease relies on patient history and physical examination, laboratory tests, chest computed tomography, positron emission tomography, and tissue confirmation of mediastinal involvement. Further evaluation for metastases depends on the clinical presentation. Treatment and prognosis are closely tied to the type and stage of the tumor identified. For stages I through IIIA non–small cell carcinoma, surgical resection is preferred. Advanced non–small cell carcinoma is treated with a multimodality approach that may include radiotherapy, chemotherapy, and palliative care. Chemotherapy (combined with radiotherapy for limited disease) is the mainstay of treatment for small cell carcinoma. No major organization recommends screening for early detection of lung cancer, although screening has interested researchers and physicians. Smoking cessation remains the critical component of preventive primary care.

Lung cancer is the leading cause of cancer-related death in the United States. In 2006, the disease caused over 158,000 deaths—more than colorectal, breast, and prostate cancers combined.1 Although death rates have begun to decline among men in the United States, the lung recently surpassed the breast as the most common origin of fatal cancer in women.2 Because one fourth of adults smoke, lung cancer will remain a problem for many years.2 Despite advances in lung cancer therapy, the average five-year survival rate is only 15 percent.3 Adenocarcinoma has surpassed squamous cell carcinoma as the most common histologic type of lung carcinoma,4,5 and early metastasis has become increasingly common.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Patients with central lung tumors should undergo flexible bronchoscopy.

C

27,28

Patients with peripheral lung tumors who are not surgical candidates should undergo transthoracic needle aspiration.

C

27,28

Patients undergoing mediastinal staging for lung cancer should receive chest computed tomography plus positron emission tomography.

C

34,35

There is insufficient evidence to recommend for or against routine screening for lung cancer.

C

4042

For lung cancer prevention, smokers should be offered nicotine replacement therapy, bupropion (Wellbutrin), nortriptyline (Pamelor), and counseling for smoking cessation.

A

5053


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 13 or http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Patients with central lung tumors should undergo flexible bronchoscopy.

C

27,28

Patients with peripheral lung tumors who are not surgical candidates should undergo transthoracic needle aspiration.

C

27,28

Patients undergoing mediastinal staging for lung cancer should receive chest computed tomography plus positron emission tomography.

C

34,35

There is insufficient evidence to recommend for or against routine screening for lung cancer.

C

4042

For lung cancer prevention, smokers should be offered nicotine replacement therapy, bupropion (Wellbutrin), nortriptyline (Pamelor), and counseling for smoking cessation.

A

5053


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 13 or http://www.aafp.org/afpsort.

Risk Factors

Smoking is the predominant risk factor for lung cancer (relative risk [RR] = 10 to 30 compared with nonsmokers)3,6; smoking is directly linked to lung cancer in 90 percent of women and 79 percent of men.7 Secondhand smoke exposure is also a risk factor.8,9 Approximately 3,000 adults die each year from exposure to secondhand smoke, with a dose-response relationship between duration and intensity of exposure.10,11

The most common occupational risk factor for lung cancer is exposure to asbestos (RR = 6)7; the RR for smokers who are exposed to asbestos approaches 60.12 Other common occupational and environmental causes of lung cancer include exposure to radon, arsenic, chromium, nickel, vinyl chloride, and ionizing radiation.13 Preexisting nonmalignant lung diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and tuberculosis also are associated with increased lung cancer rates.

Pathology

To facilitate treatment and prognostic decisions, lung cancer is categorized as small cell carcinoma or non–small cell carcinoma. Light microscopy is used to further differentiate lung cancer into four major and several minor histologic classes (Table 114,15).16 The major histologic classes are adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and large cell carcinoma.

TABLE 1

Histologic Classification of Lung Cancer

Class Prevalence (%) Subtypes

Adenocarcinoma

40

Acinar, bronchioalveolar, papillary, solid carcinoma with mucus formation, mixed

Squamous cell carcinoma

25

Small cell carcinoma

20

Pure small cell carcinoma, combined small cell carcinoma

Large cell carcinoma

10

Large cell neuroendocrine, basaloid, lymphoepithelial-like, large cell with rhabdoid phenotype

Adenosquamous carcinoma

< 5

Carcinoid

< 5

Bronchial gland carcinoma

< 5


Information from 14 and 15.

TABLE 1   Histologic Classification of Lung Cancer

View Table

TABLE 1

Histologic Classification of Lung Cancer

Class Prevalence (%) Subtypes

Adenocarcinoma

40

Acinar, bronchioalveolar, papillary, solid carcinoma with mucus formation, mixed

Squamous cell carcinoma

25

Small cell carcinoma

20

Pure small cell carcinoma, combined small cell carcinoma

Large cell carcinoma

10

Large cell neuroendocrine, basaloid, lymphoepithelial-like, large cell with rhabdoid phenotype

Adenosquamous carcinoma

< 5

Carcinoid

< 5

Bronchial gland carcinoma

< 5


Information from 14 and 15.

Adenocarcinomas are histologically heterogeneous peripheral masses that metastasize early, and often occur in patients with underlying lung disease.17 Squamous cell carcinomas typically are centrally located endobronchial masses that may present with hemoptysis, postobstructive pneumonia, or lobar collapse. Unlike adenocarcinomas, squamous cell carcinomas generally metastasize late in the disease course.

Small cell carcinomas are clinically aggressive; are usually centrally located with extensive mediastinal involvement; and are associated with early extrathoracic metastases, including paraneoplastic syndrome. Despite their responsiveness to chemotherapy, small cell carcinomas often are advanced at the time of diagnosis, and patients have a poor prognosis.19

Large cell carcinomas are poorly differentiated. These tumors are large peripheral masses associated with early metastases.17

Clinical Presentation

Although approximately 10 percent of lung cancers in asymptomatic patients are detected on chest radiographs, most patients are symptomatic when diagnosed.19  Patients may present with the nonspecific systemic symptoms of fatigue, anorexia, and weight loss, or with direct signs and symptoms caused by the primary tumor or intrathoracic or extrathoracic spread (Table 220). A minority of patients present with paraneoplastic syndromes.

TABLE 2

Common Lung Cancer Manifestations

Primary tumor

Chest discomfort

Cough

Dyspnea

Hemoptysis

Intrathoracic spread

Chest wall invasion

Esophageal symptoms

Horner syndrome

Pancoast's tumor

Phrenic nerve paralysis

Pleural effusion

Recurrent laryngeal nerve paralysis

Superior vena cava obstruction

Extrathoracic spread

Bone pain, fracture

Confusion, personality change

Elevated alkaline phosphatase level

Focal neurologic deficits

Headache

Nausea, vomiting

Palpable lymphadenopathy

Seizures

Weakness

Weight loss


Information from reference 20.

TABLE 2   Common Lung Cancer Manifestations

View Table

TABLE 2

Common Lung Cancer Manifestations

Primary tumor

Chest discomfort

Cough

Dyspnea

Hemoptysis

Intrathoracic spread

Chest wall invasion

Esophageal symptoms

Horner syndrome

Pancoast's tumor

Phrenic nerve paralysis

Pleural effusion

Recurrent laryngeal nerve paralysis

Superior vena cava obstruction

Extrathoracic spread

Bone pain, fracture

Confusion, personality change

Elevated alkaline phosphatase level

Focal neurologic deficits

Headache

Nausea, vomiting

Palpable lymphadenopathy

Seizures

Weakness

Weight loss


Information from reference 20.

PRIMARY TUMOR

Chest discomfort, cough, dyspnea, and hemoptysis are common manifestations of a primary tumor. Cough secondary to an endobronchial mass or postobstructive pneumonia occurs in up to 75 percent of patients.20 Dyspnea occurs in up to 60 percent of patients and may be caused by a tumor occluding the airway.20 Intermittent, aching chest discomfort occurs in approximately 50 percent of patients at diagnosis.20 Hemoptysis is found in up to 35 percent of patients with symptoms from a primary tumor.20 Although acute bronchitis is the most common cause of hemoptysis, lung cancer should be suspected in patients older than 40 who present with hemoptysis.20

INTRATHORACIC SPREAD

Forty percent of patients diagnosed with lung cancer initially present with signs and symptoms of intrathoracic spread. Intrathoracic spread is caused by direct extension of the tumor or lymphangitic spread.

Hoarseness from recurrent laryngeal nerve paralysis occurs in 2 to 18 percent of patients.20 Phrenic nerve paralysis may present with dyspnea or an elevated left hemidiaphragm on a chest radiograph.20 A superior pulmonary sulcus tumor (Pancoast's tumor) may present with Horner syndrome and is characterized by a brachial plexopathy and pain along the involved nerve roots.21 Chest wall invasion often presents with persistent, pleuritic pain. Pleural effusions may present with dyspnea, decreased breath sounds, and dullness to percussion.22 Esophageal obstruction may cause dysphagia. Superior vena cava obstruction is characterized by facial swelling and plethora and by dilated veins on the upper torso, shoulders, and arms.23 Although pericardial involvement often is found at autopsy, patients seldom present with symptomatic pericardial effusion or tamponade.24

EXTRATHORACIC SPREAD

Nearly one third of patients with lung cancer present with signs and symptoms of extrathoracic spread.20 Common metastatic sites include bones, liver, adrenal glands, lymph nodes, brain, and spinal cord.

Nonspecific symptoms of extrathoracic spread include weakness and weight loss. Bone metastasis often presents with pain, fracture, or elevated alkaline phosphatase level and usually involves the long bones or vertebrae. Palpable lymphadenopathy, particularly in the supraclavicular fossa, suggests metastasis. Ten percent of patients present with brain metastasis heralded by headache, nausea, vomiting, focal neurologic deficits, seizures, confusion, or personality changes.25 Although liver involvement is common, transaminase elevation is relatively rare.

PARANEOPLASTIC SYNDROMES

Approximately 10 percent of patients with lung cancer develop systemic symptoms related to paraneoplastic syndromes. This is caused by the release of bioactive substances produced by the tumor or in response to the tumor. Symptoms may precede the diagnosis, appear late in the disease course, or suggest recurrence.

Common endocrine syndromes include hypercalcemia, syndrome of inappropriate antidiuretic hormone, and Cushing's syndrome. Digital clubbing and hypertrophic pulmonary osteoarthropathy are common skeletal manifestations. Less well-defined neurologic syndromes include Lambert-Eaton myasthenic syndrome, peripheral neuropathy, and cortical cerebellar degeneration.26

Diagnosis

TISSUE DIAGNOSIS

There are a variety of techniques to assist physicians in obtaining an accurate tissue diagnosis (Table 327). Selecting the most appropriate test usually requires consultation with a pulmonologist, interventional radiologist, or thoracic surgeon. In patients with apparent early non–small cell carcinomas, who are surgical candidates, thoracotomy is the recommended test for tissue diagnosis and staging. In patients with presumed small cell or metastatic non–small cell carcinomas, the diagnosis should be made using the most convenient and least invasive method available (e.g., thoracentesis of a pleural effusion, excisional biopsy of an accessible node, bronchoscopy, transthoracic needle aspiration).27

TABLE 3

Methods for the Tissue Diagnosis of Lung Cancer

Diagnostic method Sensitivity (%) Specificity (%) Indication Comments

Sputum cytology (at least three specimens)

Central tumors: 71

99

Central tumor and hemoptysis

Noninvasive; further testing needed after negative result

Peripheral tumors: < 50

Thoracentesis

80

> 90

Pleural effusion

Excisional biopsy of an accessible node

Palpable lymphadenopathy

Flexible bronchoscopy with or without transbronchial needle aspiration

Central tumors: 88

90

Central or peripheral tumor and mediastinal lymphadenopathy

Fluoroscopic or CT guidance; transbronchial needle aspiration improves sensitivity in peripheral tumors

Peripheral tumors: 60 to 70

Transthoracic needle aspiration

Peripheral tumors: 90

97

Peripheral tumor in nonsurgical candidates or when transbronchial needle aspiration is inconclusive

Fluoroscopic or CT guidance; the assistance of a cytopathologist improves diagnostic yield

Video-assisted thoracoscopy

Small peripheral tumors (< 2 cm in diameter), pleural tumors, or pleural effusions

May prevent the need for thoracotomy

Thoracotomy

Only clearly resectable tumors

Recommended for diagnosis and treatment of early non–small cell carcinoma


CT = computed tomography.

Information from reference 27.

TABLE 3   Methods for the Tissue Diagnosis of Lung Cancer

View Table

TABLE 3

Methods for the Tissue Diagnosis of Lung Cancer

Diagnostic method Sensitivity (%) Specificity (%) Indication Comments

Sputum cytology (at least three specimens)

Central tumors: 71

99

Central tumor and hemoptysis

Noninvasive; further testing needed after negative result

Peripheral tumors: < 50

Thoracentesis

80

> 90

Pleural effusion

Excisional biopsy of an accessible node

Palpable lymphadenopathy

Flexible bronchoscopy with or without transbronchial needle aspiration

Central tumors: 88

90

Central or peripheral tumor and mediastinal lymphadenopathy

Fluoroscopic or CT guidance; transbronchial needle aspiration improves sensitivity in peripheral tumors

Peripheral tumors: 60 to 70

Transthoracic needle aspiration

Peripheral tumors: 90

97

Peripheral tumor in nonsurgical candidates or when transbronchial needle aspiration is inconclusive

Fluoroscopic or CT guidance; the assistance of a cytopathologist improves diagnostic yield

Video-assisted thoracoscopy

Small peripheral tumors (< 2 cm in diameter), pleural tumors, or pleural effusions

May prevent the need for thoracotomy

Thoracotomy

Only clearly resectable tumors

Recommended for diagnosis and treatment of early non–small cell carcinoma


CT = computed tomography.

Information from reference 27.

Several options are available when the type and stage of the cancer are less clear, including sputum cytology, flexible bronchoscopy, and transthoracic needle aspiration. Sputum cytology is a noninvasive test that may be useful in identifying centrally located tumors. The test detects 71 percent of central tumors but less than 50 percent of peripheral tumors27; therefore, further testing must follow a negative result.

Flexible bronchoscopy (employing bronchial washings, brushings, and biopsies) often is the test of choice in patients with central tumors, with a combined sensitivity of 88 percent in these patients.28 Despite the addition of fluoroscopic and computed tomography (CT) guided transbronchial needle aspiration, the sensitivity of bronchoscopy falls to 70 percent in patients with peripheral tumors and even lower in patients with a tumor less than 2 cm in diameter.28,29 Pneumothorax and bleeding are serious but uncommon complications of transbronchial needle aspiration.29

Transthoracic needle aspiration has been shown to be more sensitive than bronchoscopy in patients with peripheral lung tumors and may be used when transbronchial needle aspiration is inconclusive or in patients who are not surgical candidates.28 Transthoracic needle aspiration is routinely guided by fluoroscopy or CT, and the assistance of a cytopathologist increases the diagnostic yield. The most common complication of transthoracic needle aspiration is pneumothorax (25 to 30 percent), but the procedure rarely requires chest tube insertion.29

Video-assisted thoracoscopy is a newer modality that may be used to sample small peripheral tumors (less than 2 cm in diameter), pleural tumors, or pleural effusions for diagnostic or staging purposes.30

STAGING

After establishing a tissue diagnosis, a thorough staging work-up, including metastatic evaluation (Figure 127,2932) and staging classification, should be performed to determine the presence of metastasis and to identify surgical resection candidates.

Metastatic Evaluation of Lung Cancer

Figure 1.

Algorithm for the metastatic evaluation of lung cancer.

Information from references 27 and 29 through 32.

View Large

Metastatic Evaluation of Lung Cancer


Figure 1.

Algorithm for the metastatic evaluation of lung cancer.

Information from references 27 and 29 through 32.

Metastatic Evaluation of Lung Cancer


Figure 1.

Algorithm for the metastatic evaluation of lung cancer.

Information from references 27 and 29 through 32.

Initial evaluation for metastasis can be performed by the primary care physician and includes a detailed history; physical examination; complete blood count; and levels of electrolyte, calcium, hepatic transaminases, and alkaline phosphatase. More than 80 percent of patients with an abnormality on evaluation have metastatic disease.31 Patients presenting with anorexia, weight loss, and fatigue have an especially poor prognosis.33

Noninvasive radiographic imaging with chest CT and positron emission tomography (PET) scans is routinely performed in patients with suspected metastatic lung cancer. Chest and upper abdomen CT scans may reveal hilar and mediastinal adenopathy and liver or adrenal involvement. Although CT accuracy is 88 percent (80 percent sensitive, 100 percent specific) in the mediastinum, staging is enhanced by PET.34 Integrated CT/PET scanners appear to have better test characteristics than CT or PET alone.35

In patients with suspected mediastinal disease, the remainder of the mediastinal staging evaluation usually is performed in consultation with subspecialists and may include bronchoscopy with or without transbronchial needle aspiration, endobronchial ultrasonography–guided transbronchial needle aspiration, transthoracic needle aspiration, video-assisted thoracoscopy, or mediastinoscopy. The clinical presentation dictates the use of additional staging measures. Abdominal CT, bone scanning, and brain magnetic resonance imaging are usually recommended in patients with small cell carcinoma because of the high likelihood of metastatic disease.

After the metastatic evaluation is complete, the staging classification (Table 436) can be determined based on the type of tumor identified and the presence or absence of metastatic disease. Non–small cell carcinoma is categorized using the TNM (tumor-nodes-metastasis) staging system, whereas small cell carcinoma is categorized as limited disease confined to the ipsilateral hemithorax or as extensive disease with metastasis beyond the ipsilateral hemithorax.16

TABLE 4

Staging Classifications for Lung Cancer

Stage Description

Non–small cell carcinoma (TNM staging system)

Local

IA (T1N0M0)

T1: 3 cm or less in diameter; surrounded by lung or pleura; does not invade main bronchus

IB (T2N0M0)

T2: more than 3 cm in diameter; may invade pleura; may extend into main bronchus but remains 2 cm or more distal to carina; may cause segmental atelectasis or pneumonitis

IIA (T1N1M0)

N1: involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes

Locally advanced

IIB (T2N1M0 and T3N0M0)

T3: invasion of chest wall, diaphragm, pleura, or pericardium; main bronchus less than 2 cm distal to carina; atelectasis of entire lung

IIIA (T1N2M0, T2N2M0, T3N1M0, and T3N2M0)

N2: involvement of ipsilateral mediastinal or subcarinal nodes

IIIB (T1-4N3M0)

N3: involvement of contralateral nodes or any supraclavicular nodes

Advanced

IIIB (T4N1-3M0)

T4: invasion of mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina; separate tumor nodules; malignant pleural effusion

IV (T1-4N1-3M1)

Distant metastasis

Small cell carcinoma

Limited

Disease confined to the ipsilateral hemithorax

Extensive

Disease with metastasis beyond the ipsilateral hemithorax


TNM = tumor-nodes-metastasis.

Adapted with permission from Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:382.

TABLE 4   Staging Classifications for Lung Cancer

View Table

TABLE 4

Staging Classifications for Lung Cancer

Stage Description

Non–small cell carcinoma (TNM staging system)

Local

IA (T1N0M0)

T1: 3 cm or less in diameter; surrounded by lung or pleura; does not invade main bronchus

IB (T2N0M0)

T2: more than 3 cm in diameter; may invade pleura; may extend into main bronchus but remains 2 cm or more distal to carina; may cause segmental atelectasis or pneumonitis

IIA (T1N1M0)

N1: involvement of ipsilateral peribronchial or hilar nodes and intrapulmonary nodes

Locally advanced

IIB (T2N1M0 and T3N0M0)

T3: invasion of chest wall, diaphragm, pleura, or pericardium; main bronchus less than 2 cm distal to carina; atelectasis of entire lung

IIIA (T1N2M0, T2N2M0, T3N1M0, and T3N2M0)

N2: involvement of ipsilateral mediastinal or subcarinal nodes

IIIB (T1-4N3M0)

N3: involvement of contralateral nodes or any supraclavicular nodes

Advanced

IIIB (T4N1-3M0)

T4: invasion of mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina; separate tumor nodules; malignant pleural effusion

IV (T1-4N1-3M1)

Distant metastasis

Small cell carcinoma

Limited

Disease confined to the ipsilateral hemithorax

Extensive

Disease with metastasis beyond the ipsilateral hemithorax


TNM = tumor-nodes-metastasis.

Adapted with permission from Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:382.

FUNCTIONAL EVALUATION

The final component of the diagnostic assessment is a functional evaluation of the patient. Evaluation of performance and pulmonary status should be completed before discussing treatment options. Pulmonary function testing, specifically forced expiratory volume in one second (FEV1) and carbon monoxide diffusion in the lung (DLCO) measurements, is a helpful predictor of morbidity and mortality in patients undergoing lung resection.15

Patients with an FEV1 or DLCO value less than 80 percent of predicted require additional testing. This includes calculation of postresection pulmonary reserve (with ventilation and perfusion scans or by accounting for the number of segments removed); cardiopulmonary exercise testing (with a maximum volume of oxygen utilization [VO2max] measurement); and arterial blood gas sampling (with an oxygen saturation in arterial blood [SaO2] measurement). Patients with a predicted postoperative FEV1 or DLCO value less than 40 percent and a VO2max value less than 10 mL per kg per minute or an SaO2 value less than 90 percent are at high risk of perioperative death or complications.36

Treatment and Prognosis

Treatment differs according to the histologic type of cancer, the stage at presentation, and the patient's functional evaluation (Table 536). Surgery is the treatment of choice for patients with stage I through IIIA non–small cell carcinoma.37 Recent data suggest that preoperative chemotherapy improves survival in patients with non–small cell carcinoma.38 For patients undergoing complete resection and no preoperative chemotherapy, adjuvant chemotherapy is standard. Randomized controlled clinical trials should address the issue of preoperative versus postoperative adjuvant treatment.38

TABLE 5

Treatment of Lung Cancer According to Stage

Stage Primary treatment Adjuvant therapy Five-year survival rate (%)

Non–small cell carcinoma

I

Resection

Chemotherapy

60 to 70

II

Resection

Chemotherapy with or without radiotherapy

40 to 50

IIIA (resectable)

Resection with or without preoperative chemotherapy

Chemotherapy with or without radiotherapy

15 to 30

IIIA (unresectable) or IIIB (involvement of contralateral or supraclavicular lymph nodes)

Chemotherapy with concurrent or subsequent radiotherapy

None

10 to 20

IIIB (pleural effusion) or IV

Chemotherapy or resection of primary brain metastasis and primary T1 tumor

None

10 to 15 (two-year survival)

Small cell carcinoma

Limited disease

Chemotherapy with concurrent radiotherapy

None

15 to 25

Extensive disease

Chemotherapy

None

< 5


Adapted with permission from Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:388.

TABLE 5   Treatment of Lung Cancer According to Stage

View Table

TABLE 5

Treatment of Lung Cancer According to Stage

Stage Primary treatment Adjuvant therapy Five-year survival rate (%)

Non–small cell carcinoma

I

Resection

Chemotherapy

60 to 70

II

Resection

Chemotherapy with or without radiotherapy

40 to 50

IIIA (resectable)

Resection with or without preoperative chemotherapy

Chemotherapy with or without radiotherapy

15 to 30

IIIA (unresectable) or IIIB (involvement of contralateral or supraclavicular lymph nodes)

Chemotherapy with concurrent or subsequent radiotherapy

None

10 to 20

IIIB (pleural effusion) or IV

Chemotherapy or resection of primary brain metastasis and primary T1 tumor

None

10 to 15 (two-year survival)

Small cell carcinoma

Limited disease

Chemotherapy with concurrent radiotherapy

None

15 to 25

Extensive disease

Chemotherapy

None

< 5


Adapted with permission from Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:388.

Treatment for unresectable non–small cell carcinoma may involve radiotherapy and chemotherapy. The role of targeted therapies, specifically the antivascular endothelial growth factor agent bevacizumab (Avastin), has been examined in patients with advanced stage (IIIB and IV) nonsquamous carcinoma. Bevacizumab combined with chemotherapy increased survival compared with chemotherapy alone.39 Chemotherapy (combined with radiotherapy in limited stage disease) is the mainstay of treatment for small cell carcinoma.37

Palliative and hospice care are important end-of-life treatment modalities. The primary care physician can help patients determine what options may be most appropriate. Table 6 includes hospice and palliative care resources.

TABLE 6

Hospice and Palliative Care Resources

American Academy of Hospice and Palliative Medicine Web site: http://www.aahpm.org

American Board of Hospice and Palliative Medicine Web site: http://www.abhpm.org

American Pain Society Web site: http://www.ampainsoc.org

Americans for Better Care of the Dying Web site: http://www.abcd-caring.org

Approaching Death: Improving Care at the End of Life Publisher: The National Academies Press

Before I Die: Medical Care and Personal Choices Web site: http://www.wnet.org/bid/index.html

City of Hope Pain/Palliative Care Resource Center Web site: http://www.cityofhope.org/prc

Dying Well: Defining Wellness Through the End of Life Web site: http://www.dyingwell.org

End of Life/Palliative Education Resource Center Web site: http://www.eperc.mcw.edu

EndLink Resource for End of Life Care Education Web site: http://endlink.lurie.northwestern.edu

TABLE 6   Hospice and Palliative Care Resources

View Table

TABLE 6

Hospice and Palliative Care Resources

American Academy of Hospice and Palliative Medicine Web site: http://www.aahpm.org

American Board of Hospice and Palliative Medicine Web site: http://www.abhpm.org

American Pain Society Web site: http://www.ampainsoc.org

Americans for Better Care of the Dying Web site: http://www.abcd-caring.org

Approaching Death: Improving Care at the End of Life Publisher: The National Academies Press

Before I Die: Medical Care and Personal Choices Web site: http://www.wnet.org/bid/index.html

City of Hope Pain/Palliative Care Resource Center Web site: http://www.cityofhope.org/prc

Dying Well: Defining Wellness Through the End of Life Web site: http://www.dyingwell.org

End of Life/Palliative Education Resource Center Web site: http://www.eperc.mcw.edu

EndLink Resource for End of Life Care Education Web site: http://endlink.lurie.northwestern.edu

Screening

Although studies have assessed screening with sputum cytology, routine chest radiography, and low-dose CT, no study has demonstrated that screening improves survival, and no major organization currently endorses lung cancer screening.40 In 2004, the U.S. Preventive Services Task Force concluded that although there is fair evidence that screening may allow for earlier detection of lung cancer, there is poor evidence to suggest that any screening strategy decreases mortality.41 With no proven effect of screening on mortality rates, there is concern that screening may cause overdiagnoses and unnecessary anxiety, radiation exposure, and expense.42

Several large randomized controlled trials designed to evaluate the effect of screening on mortality are underway.43,44 Until these results become available, there is insufficient evidence to recommend for or against routine screening.

Prevention

Perhaps the primary care physician's most important role is preventing lung cancer by encouraging smoking cessation. The most effective cessation therapies (with quit rates ranging from 16 to 21 percent) are nicotine replacement, bupropion (Wellbutrin), nortriptyline (Pamelor), and structured telephone counseling.4553 Combining nicotine replacement, bupropion, and social or behavioral support can increase the quit rate to 35 percent.54 Informal counseling by physicians has also been shown to modestly increase quit rates.55,56

The Authors

LAUREN G. COLLINS, M.D., is an assistant professor in the Department of Family Medicine at Thomas Jefferson University Hospital and Jefferson Medical College, Philadelphia, Pa. She received her medical degree from Jefferson Medical College, and completed a family medicine residency and geriatrics fellowship at Thomas Jefferson University Hospital.

CHRISTOPHER HAINES, M.D., is a clinical instructor in the Department of Family Medicine at Thomas Jefferson University Hospital and Jefferson Medical College. He received his medical degree from Jefferson Medical College and completed a family medicine residency at Thomas Jefferson University Hospital.

ROBERT PERKEL, M.D., is a clinical professor in the Department of Family Medicine at Thomas Jefferson University Hospital and Jefferson Medical College. He received his medical degree from the Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y., and completed a family medicine residency at Thomas Jefferson University Hospital.

ROBERT E. ENCK, M.D., is a clinical professor in the Department of Family Medicine at Thomas Jefferson University Hospital and Jefferson Medical College. He received his medical degree from Hahnemann Medical College, Philadelphia, Pa., and completed a family medicine residency at Hahnemann University Hospital. He completed a medical oncology fellowship at the University of Rochester (N.Y.).

Address correspondence to Lauren G. Collins, M.D., Thomas Jefferson University, 1015 Walnut St., Suite 401, Philadelphia, PA 19107 (e-mail: guslaurie@yahoo.com). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. American Cancer Society. Statistics for 2006. Accessed October 6, 2006, at: http://www.cancer.org/docroot/stt/stt_0.asp.

2. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 1999 [Published correction appears in MMWR Morb Mortal Wkly Rep 2001;50:1066]. MMWR Morb Mortal Wkly Rep. 2001;50:869–73.

3. American Cancer Society. Statistics for 2003. Accessed October 6, 2006, at: http://www.cancer.org/docroot/stt/stt_0_2003.asp

4. Vaporciyan AA, Nesbitt JC, Lee J, Stevens C, Komaki R, Roth JA. Cancer of the lung. In: Cancer Medicine. 5th ed. Lewiston, N.Y.: Decker, 2000.

5. Vincent RG, Pickren JW, Lane WW, Bross I, Takita H, Houten L, et al. The changing histopathology of lung cancer: a review of 1,682 cases. Cancer. 1977;39:1647–55.

6. Centers for Disease Control and Prevention. The health consequences of smoking. A report of the surgeon general. 2004. Accessed October 6, 2006, at: http://www.cdc.gov/tobacco/sgr/sgr_2004/index.htm.

7. Bilello KS, Murin S, Matthay RA. Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med. 2002;23:1–25.

8. Fontham ET, Correa P, Reynolds P, Wu-Williams A, Buffler PA, Greenberg RS, et al. Environmental tobacco smoke and lung cancer in non-smoking women. A multicenter study [Published correction appears in JAMA 1994;272:1578]. JAMA. 1994;271:1752–9.

9. Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. Washington, D.C.: Environmental Protection Agency, 1992. Accessed November 27, 2006, at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=2835.

10. Wu AH, Fontham ET, Reynolds P, Greenberg RS, Buffler P, Liff J, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol. 1996;143:535–42.

11. Boffetta P, Agudo A, Ahrens W, Benhamou E, Benhamou S, Darby SC, et al. Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. J Natl Cancer Inst. 1998;90:1440–50.

12. Hammond EC, Selikoff IJ, Seidman H. Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci. 1979;330:473–90.

13. Gilliland FD, Hunt WC, Pardilla M, Key CR. Uranium mining and lung cancer among Navajo men in New Mexico and Arizona, 1969 to 1993. J Occup Environ Med. 2000;42:278–83.

14. Travis WD. Pathology of lung cancer. Clin Chest Med. 2002;23:65–81.

15. Hoffman PC, Mauer AM, Vokes EE. Lung cancer [Published correction appears in Lancet 2000;355:1280]. Lancet. 2000;355:479–85.

16. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–7.

17. Travis WD, Travis LB, Devesa SS. Lung cancer [Published correction appears in Cancer 1995;75:2979]. Cancer. 1995;75(1 suppl):191–202.

18. Patz EF Jr. Imaging bronchogenic carcinoma. Chest. 2000;117(4 suppl 1):90S–5S.

19. Midthun DE, Jett JR. Clinical presentation of lung cancer. In: Lung Cancer: Principles and Practice. Philadelphia, Pa.: Lippincott-Raven, 1996:421.

20. Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003;123(1 suppl):97S–104S.

21. Paulson DL. Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg. 1975;70:1095–104.

22. Rodriguez-Panadero F, Borderas Naranjo F, Lopez Mejias J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a postmortem series. Eur Respir J. 1989;2:366–9.

23. Wudel LJ Jr, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001;2:77–91.

24. Press OW, Livingston R. Management of malignant pericardial effusion and tamponade. JAMA. 1987;257:1088–92.

25. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 1989;149:1076–80.

26. Patel AM, Davila DG, Peters SG. Paraneoplastic syndromes associated with lung cancer. Mayo Clinic Proc. 1993;68:278–87.

27. Rivera MP, Detterbeck F, Mehta AC, for the American College of Chest Physicians. Diagnosis of lung cancer: the guidelines. Chest. 2003;123(1 suppl):129S36S.

28. Arroliga AC, Matthay RA. The role of bronchoscopy in lung cancer. Clin Chest Med. 1993;14:87–98.

29. Mazzone P, Jain P, Arroliga AC, Matthay RA. Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med. 2002;23:137–58.

30. Mentzer SJ, Swanson SJ, DeCamp MM, Bueno R, Sugarbaker DJ. Mediastinoscopy, thoracoscopy, and video-assisted thoracic surgery in the diagnosis and staging of lung cancer. Chest. 1997;112(4 suppl):239S–41S.

31. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med. 1995;152:225–30.

32. Yasufuku K, Nakajima T, Motoori K, Sekine Y, Shibuya K, Hiroshima K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest. 2006;130:710–8.

33. Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine. 1990;69:1–33.

34. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Thorax. 1997;52:438–41.

35. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.

36. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.

37. Beckles MA, Spiro SG, Colice GL, Rudd RM, for the American College of Chest Physicians. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest. 2003;123(1 suppl):105S–14S.

38. National Comprehensive Cancer Network. Non-small cell lung cancer. Version 2.2006. Accessed October 6, 2006, at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf#search=%22abstract%20no%3ALBA7012%22.

39. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial—E4599. Accessed October 6, 2006, at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d /?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=33325.

40. Humphrey LL, Teutsch S, Johnson M, for the U.S. Preventive Services Task Force. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:740–53.

41. U.S. Preventive Services Task Force. Lung cancer screening: recommendation statement. Ann Intern Med. 2004;140:738–9.

42. Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. Cochrane Database Syst Rev. 2004;(1):CD001991.

43. Gohagan JK, Prorok PC, Hayes RB, Kramer BS, for the Prostate, Lung Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 suppl):251S-72S.

44. National Cancer Institute. National Lung Screening Trial. Accessed October 2, 2006, at: http://www.cancer.gov/nlst/what-is-nlst.

45. Kripke C. Antidepressants and smoking cessation. Am Fam Physician. 2005;71:67–8.

46. Talwar A, Jain M, Vijayan VK. Pharmacotherapy of tobacco dependence. Med Clin North Am. 2004;88:1517–34.

47. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J. Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med. 2003;114:555–62.

48. Jimenez-Ruiz C, De Granda Orive JI. Success rates for nortriptyline. Chest. 2003;124:768–9.

49. Osinubi OY, Moline J, Rovner E, Sinha S, Perez-Lugo M, Demissie K, et al. A pilot study of telephone-based smoking cessation intervention in asbestos workers. J Occup Environ Med. 2003;45:569–74.

50. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000031.

51. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292.

52. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001007.

53. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.

54. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91.

55. Jorenby DE, Fiore MC. The Agency for Health Care Policy and Research smoking cessation clinical practice guideline: basics and beyond. Prim Care. 1999;26:513–28.

56. Mallin R. Smoking cessation: integration of behavioral and drug therapies. Am Fam Physician. 2002;65:1107–14.


Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article